<DOC>
	<DOCNO>NCT02862613</DOCNO>
	<brief_summary>Objectives : To evaluate safety effectiveness cell therapy use Precision Cells Combined With TACE Advanced Liver Cancer . Eligibility : Individuals great equal 18 year age less equal 65 year age diagnose Advanced Liver Cancer .</brief_summary>
	<brief_title>Precision Cell Immunotherapy Combined With TACE Advanced Liver Cancer</brief_title>
	<detailed_description>A total 40 patient may enrol period 1-2 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Age 18~65 year old , male female ; Life expectancy≥6 month ; ECOG score : 03 ; Advanced Malignancies ( lung cancer , gastric cancer ) diagnose pathological clinical physician , Diagnosis hepatocellular carcinoma ( HCC ) , surgery perform TACE treatment carry ; Enough venous channel , contraindication separation collection white blood cell ; Laboratory examination : white blood cell≥3 x 10*9/L , blood platelet count≥60 x 10*/L , hemoglobin≥85g/L ; lymphocyte count≥15 % , total bilirubin≤100 mol/L ; ALT AST less five time normal level ; serum creatinine less 1.5 time normal level ; Signed informed consent ; Women childbearing age must evidence negative pregnancy test willing practice birth control 2 week follow cell transfusion . Expected Overall survival ＜ 3 month ; The tumor size quantity suitable interventional treatment portal vein tumor thrombus ; Liver function Childs Pugh C ; Had receive TACE therapy previously radiotherapy present , take Sola Feeney ; Other serious disease : heart , lung , kidney , digestive , nervous , mental disorder , immune regulatory disease , metabolic disease , infectious disease , etc ; Unable unwilling provide inform consent , fail comply test requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Precision Cells</keyword>
	<keyword>Transcatheter Arterial Chemoembolization</keyword>
	<keyword>Advanced Liver Cancer</keyword>
</DOC>